1-2-dilauroylphosphatidylcholine and Fatty-Liver
1-2-dilauroylphosphatidylcholine has been researched along with Fatty-Liver* in 3 studies
Reviews
1 review(s) available for 1-2-dilauroylphosphatidylcholine and Fatty-Liver
Article | Year |
---|---|
[New pathophysiological mechanisms of metabolic syndrome: implication of orphan nuclear receptors?].
This review focuses on a number of new data on biology and pathophysiology of the metabolic syndrome (MetS) and the involvement of nuclear receptors that have been presented during the last Endocrine Society meeting, held in Houston in June 2012. Several studies have reported beneficial effects of various orphan nuclear receptors, including SHP (Small Heterodimeric Partner, NR0B2) and LXR (Liver X Receptor, NR1H3 and NR1H2), on various components of MetS. By using an inactivation model of SHP, David Moore has shown that SHP exerts "antidiabetic" effects but associated with hepatic steatosis development. He also showed that DLPC (dilauroyl phosphatidylcholine), an unconventional phospholipid, exhibited anti-diabetic properties through its binding to LRH-1 (Liver Receptor Homolog-1, NR5A2), a molecular partner of SHP. Interestingly, Carolyn Cummins investigated LXR α and β isoforms knock-out mice and provided experimental evidence for the detailed mechanisms involved in the deleterious metabolic effects of glucocorticoids, pointing out to the functional interaction between LXRβ, and the glucocorticoid receptor. These new and original studies open new therapeutic opportunities for the management of metabolic disorders in humans by selective modulators of these receptors. Topics: Animals; Fatty Liver; Glucocorticoids; Humans; Hypoglycemic Agents; Liver X Receptors; Metabolic Syndrome; Mice; Mice, Knockout; Orphan Nuclear Receptors; Phosphatidylcholines; Receptors, Cytoplasmic and Nuclear | 2012 |
Other Studies
2 other study(ies) available for 1-2-dilauroylphosphatidylcholine and Fatty-Liver
Article | Year |
---|---|
A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects.
Nuclear hormone receptors regulate diverse metabolic pathways and the orphan nuclear receptor LRH-1 (also known as NR5A2) regulates bile acid biosynthesis. Structural studies have identified phospholipids as potential LRH-1 ligands, but their functional relevance is unclear. Here we show that an unusual phosphatidylcholine species with two saturated 12 carbon fatty acid acyl side chains (dilauroyl phosphatidylcholine (DLPC)) is an LRH-1 agonist ligand in vitro. DLPC treatment induces bile acid biosynthetic enzymes in mouse liver, increases bile acid levels, and lowers hepatic triglycerides and serum glucose. DLPC treatment also decreases hepatic steatosis and improves glucose homeostasis in two mouse models of insulin resistance. Both the antidiabetic and lipotropic effects are lost in liver-specific Lrh-1 knockouts. These findings identify an LRH-1 dependent phosphatidylcholine signalling pathway that regulates bile acid metabolism and glucose homeostasis. Topics: Animals; Bile Acids and Salts; Blood Glucose; Cell Line; Disease Models, Animal; Fatty Liver; HeLa Cells; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphatidylcholines; Protein Binding; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Triglycerides | 2011 |
Metabolism: A lipid for fat disorders.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Bile Acids and Salts; Fatty Liver; Humans; Insulin Resistance; Liver; Mice; Phosphatidylcholines; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2011 |